US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Monkeypox Concept

1,578.76

+20.121.29%

Number of Gainers:5

Number of Losers:6

Number of Flat:1

PE:- -

High:1,590.27

Open:1,558.43

Low:1,544.07

Close:1,558.63

Loading ...

Fresenius Medical Care Divests Laboratory Assets to Quest Diagnostics

Gilead Sciences Says Potential HIV Prophylaxis Applications Under Parallel Accelerated Review in EU

MT Newswires Live

GeoVax Highlights the Role of MVA-Based Vaccines in Advancing Public Health Preparedness

TNXP: PDUFA Date for TNX-102 SL in Fibromyalgia of August 15, 2025…

Zacks Small Cap Research

Quest Diagnostics to Acquire Select Laboratory Assets of Fresenius Medical Care Unit

MT Newswires Live

European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for Hiv Prevention

THOMSON REUTERS

Gilead: Both Applications of Lenacapavir for Hiv Prevention Will Be Assessed in Parallel Under Accelerated Assessment Review Timeline

THOMSON REUTERS

European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention

Fresenius Medical divesting select laboratory assets to Quest Diagnostics

BRIEF-FMC AG Divests Select Laboratory Assets To Quest Diagnostics

FMC Ag - Transition of Services Is Expected to Be Complete by Early 2026.

THOMSON REUTERS

FMC Ag - Acquisition Is Expected to Close in Second Half of 2025

THOMSON REUTERS

FMC Ag - Financial Terms Were Not Disclosed

THOMSON REUTERS

Fresenius Medical Care Announces Divestment of Select Laboratory Assets to Quest Diagnostics

THOMSON REUTERS

Press Release: Fresenius Medical Care Announces Divestment of Select Laboratory Assets to Quest Diagnostics

Gilead Sciences, Inc. (GILD): Among Renaissance Technologies Portfolio’s Top Stock Picks

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4583/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4583"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","market":"US","secType":"PLATE","nameCN":"Monkeypox Concept","latestPrice":1578.755,"timestamp":1741381199999,"preClose":1558.6333,"halted":0,"volume":42680690,"delay":0,"changeRate":0.01291,"change":20.121704,"pbRate":3.862886,"amount":2116926500.978348,"amplitude":0.02964,"prevYearClose":1284.7982,"fiveDayClose":1535.672,"twentyDayClose":1365.0785,"turnoverRate":0.015205,"marketCap":178874554549,"floatMarketCap":178075923317.5,"peRate":763.774353},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","high":1590.2714,"amplitude":0.02964,"preClose":1558.6333,"low":1544.0729,"pbRate":"3.862886","latestPrice":1578.755,"volume":42680690,"delay":0,"open":1558.4325,"prevYearClose":1284.7982,"prevWeekClose":1535.672,"prevMonthClose":1535.672,"prevQuarterClose":1284.7982,"fiveDayClose":1535.672,"twentyDayClose":1365.0785,"sixtyDayClose":1289.4387,"secType":"PLATE","market":"US","turnoverRate":0.015205,"peRate":763.774353,"marketCap":178874554549,"floatMarketCap":178075923317.5,"timestamp":1741381199999,"nameCN":"Monkeypox Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4583\",,,,undefined,":{"bkCode":"BK4583","up":5,"down":6,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4583\",pageSize:16,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2513209247","title":"Fresenius Medical Care Divests Laboratory Assets to Quest Diagnostics","url":"https://stock-news.laohu8.com/highlight/detail?id=2513209247","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513209247?lang=en_us&edition=fundamental","pubTime":"2025-02-24 22:57","pubTimestamp":1740409033,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Fresenius Medical Care ( ($FMS) ). On February 24, 2025, Fresenius Medical Care announced the divestment of sel...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fresenius-medical-care-divests-laboratory-assets-to-quest-diagnostics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fresenius-medical-care-divests-laboratory-assets-to-quest-diagnostics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU1854104046.USD","BK4196","BK4588","LU1854103824.USD","DGX","BK4583","BK4567"],"gpt_icon":0},{"id":"2513722106","title":"Gilead Sciences Says Potential HIV Prophylaxis Applications Under Parallel Accelerated Review in EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2513722106","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513722106?lang=en_us&edition=fundamental","pubTime":"2025-02-24 22:39","pubTimestamp":1740407986,"startTime":"0","endTime":"0","summary":"Gilead Sciences  said Monday its two applications for lenacapavir as a pre-exposure prophylaxis to prevent HIV have been validated for parallel accelerated review by the European Medicines Agency.The company said one application is for a marketing authorization and another is an EU-Medicines for all, or EU-M4all, application to facilitate expedited review processes for the injectable HIV-1 capsid inhibitor in other countries outside the EU.Both applications are supported by phase 3 data that showed twice-yearly lenacapavir achieved risk reduction in HIV infections of 96% to 100%, the company added.Gilead Sciences said the EMA validation followed the acceptance by the US Food and Drug Administration of its new drug applications for lenacapavir.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1066051498.USD","GILD","BK4585","LU2468319806.SGD","IE00BKVL7J92.USD","LU1839511570.USD","LU2087621335.USD","LU1066053197.SGD","BK4532","IE00BZ1G4Q59.USD","LU0058720904.USD","LU2089984988.USD","IE00B7SZLL34.SGD","BK4550","LU0234570918.USD","IE00BSNM7G36.USD","LU0109394709.USD","LU1571399168.USD","IE0002270589.USD","BK4568","BK4583","LU0889565916.HKD","IE00B3T34201.USD","BK4578","LU0320765992.SGD","IE00B19Z3B42.SGD","BK4139","LU1585245621.USD","BK4566","BK4588","LU1430594728.SGD","LU0289739699.SGD","BK4156","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2513724718","title":"GeoVax Highlights the Role of MVA-Based Vaccines in Advancing Public Health Preparedness","url":"https://stock-news.laohu8.com/highlight/detail?id=2513724718","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513724718?lang=en_us&edition=fundamental","pubTime":"2025-02-24 22:00","pubTimestamp":1740405600,"startTime":"0","endTime":"0","summary":"Recent Studies Support Diversified Vaccine Strategies, Aligning with GeoVax's MVA-Based GEO-CM04S1 for Enhanced Protection, Particularly for Immunocompromised Populations. ATLANTA, GA - February 24, 2025  - GeoVax Labs, Inc. , a clinical-stage biotechnology company specializing in immunotherapies and vaccines, today reaffirms the critical role that mRNA vaccines have played in combating the COVID-19 pandemic and highlights the growing recognition of the need for complementary vaccine platforms, particularly for immunocompromised patients and those requiring broader, more durable immunity.The rapid development and deployment of mRNA vaccines were pivotal in mitigating the initial impact of the pandemic, offering a timely and effective response. However, the scientific literature continues to underscore the importance of a diversified vaccine strategy directed towards enhanced durability and expanded protection against variants for populations that may not mount a sufficiently strong imm","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-highlights-role-mva-based-140000814.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4009","S","BK4568","R","BK4139","BK4585","BK4561","BK4022","GOVX","BNTX","BK4583","BK4535","GOVXW","BK4097","LU2286300806.USD","BK4548","BK4588","BK4232","HHS","BK4539","BK4560","BK4551"],"gpt_icon":0},{"id":"2514777978","title":"TNXP: PDUFA Date for TNX-102 SL in Fibromyalgia of August 15, 2025…","url":"https://stock-news.laohu8.com/highlight/detail?id=2514777978","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514777978?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:41","pubTimestamp":1740404460,"startTime":"0","endTime":"0","summary":"PDUFA Date of August 15, 2025 for NDA TNX-102 SL in Fibromyalgia. On December 23, 2024, Tonix Pharmaceuticals Holding Corp.  announced that the FDA assigned a Prescription Drug User Fee Act  target date of August 15, 2025 for a decision on the NDA filing for TNX-102 SL for the management of fibromyalgia.Pre-commercialization activities are currently underway. Tonix’s commercialization unit currently markets Zembrace and Tosymra, which are both indicated for the treatment of acute migraine in adults. Thus, Tonix will not be establishing commercial operations for TNX-102 SL from scratch but will be building upon the infrastructure that already exists. Tonix also had a market opportunity analysis conducted by EVERSANA. Overall, the analysis found a high level","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tnxp-pdufa-date-tnx-102-134100933.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TNXP","SGXZ58947870.SGD","BK4588","BK4548","LU0572939691.SGD","LU0979878070.USD","SG9999005177.SGD","BK4581","LU0532188223.SGD","LU0516423091.SGD","SG9999013478.USD","BK4583","SG9999002406.SGD","LU0251143029.SGD","LU0516422366.SGD","SG9999013460.SGD","SG9999004360.SGD","LU0264606111.USD","SG9999002679.SGD","LU2045819591.USD","IE0034224299.USD","BK4139","BK4085","LU0516422952.EUR","BK4554","LU2125910500.SGD","LU0737861269.HKD","SG9999001135.SGD","SG9999002414.USD","SG9999006266.SGD","LU0516422440.USD","SG9999002604.SGD","LU0516423174.USD","LU0572940350.SGD","SG9999002620.SGD","BK4503","BK4551","SG9999013486.USD","LU0210637038.USD","LU1242518857.USD","SG9999014492.USD","LU0048573645.USD","LU1242518931.SGD","BK4566","SG9999014484.SGD","BK4585","BK4535","LU0261945553.USD"],"gpt_icon":1},{"id":"2513901729","title":"Quest Diagnostics to Acquire Select Laboratory Assets of Fresenius Medical Care Unit","url":"https://stock-news.laohu8.com/highlight/detail?id=2513901729","media":"MT Newswires Live","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513901729?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:30","pubTimestamp":1740403815,"startTime":"0","endTime":"0","summary":"Quest Diagnostics (DGX) agreed to acquire select assets of Fresenius Medical Care's (FMS) Spectra Laboratories unit, which provides renal-specific laboratory testing services in the US, the companies ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4567","DGX","BK4196","FMS","BK4585","BK4588","LU1854103824.USD","LU1854104046.USD","SLCT","BK7129","FMS.AU","BK4583"],"gpt_icon":1},{"id":"2513299007","title":"European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for Hiv Prevention","url":"https://stock-news.laohu8.com/highlight/detail?id=2513299007","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513299007?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:30","pubTimestamp":1740403801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nTUABNG9BW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BKVL7J92.USD","BK4550","IE0002270589.USD","IE00B7SZLL34.SGD","LU0320765992.SGD","IE00BZ1G4Q59.USD","BK4588","LU0289739699.SGD","LU1066053197.SGD","BK4139","IE00B3T34201.USD","LU0889565916.HKD","BK4566","BK4532","IE00B19Z3581.USD","LU0109394709.USD","LU0234570918.USD","LU1066051498.USD","BK4585","LU2087621335.USD","LU1585245621.USD","IE00B19Z3B42.SGD","BK4568","LU0058720904.USD","LU1430594728.SGD","BK4578","BK4583","LU1571399168.USD","LU1839511570.USD","IE00BSNM7G36.USD","GILD","LU2089984988.USD","LU2468319806.SGD"],"gpt_icon":0},{"id":"2513151729","title":"Gilead:  Both Applications of Lenacapavir for Hiv Prevention Will Be Assessed in Parallel Under Accelerated Assessment Review Timeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2513151729","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513151729?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:30","pubTimestamp":1740403801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nTUABNG9BW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4583","BK4578","BK4585","IE0002270589.USD","LU2089984988.USD","BK4550","BK4566","BK4588","LU1430594728.SGD","LU1585245621.USD","IE00B19Z3B42.SGD","IE00B19Z3581.USD","LU0889565916.HKD","IE00BSNM7G36.USD","GILD","LU0234570918.USD","IE00B3T34201.USD","IE00BZ1G4Q59.USD","LU1066053197.SGD","LU1066051498.USD","LU2468319806.SGD","LU0058720904.USD","LU0109394709.USD","BK4532","LU2087621335.USD","LU0320765992.SGD","IE00BKVL7J92.USD","BK4139","LU0289739699.SGD","BK4568","IE00B7SZLL34.SGD","LU1839511570.USD","LU1571399168.USD"],"gpt_icon":0},{"id":"2513210957","title":"European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention","url":"https://stock-news.laohu8.com/highlight/detail?id=2513210957","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513210957?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:30","pubTimestamp":1740403800,"startTime":"0","endTime":"0","summary":"– One Application Seeks European Commission Authorization; Other Application Would Facilitate Availability in Low- and Lower-Middle-Income Countries –。The EMA validation follows the announcement last week that the U.S. Food and Drug and Administration  accepted Gilead’s New Drug Applications  for lenacapavir for PrEP and will assess them under priority review.The EMA applications are supported by data from the Phase 3 PURPOSE 1 and PURPOSE 2 trials conducted by Gilead. In PURPOSE 1 , data showed twice-yearly lenacapavir demonstrated zero infections in the lenacapavir group and 100% risk reduction and superiority compared to background HIV incidence  for the investigational use of HIV prevention in cisgender women. In PURPOSE 2 , there were two HIV infections in the lenacapavir group, demonstrating 99.9% of participants in the lenacapavir group did not acquire HIV infection, a 96% risk reduction in HIV infections, and superiority compared to bHIV among a broad and geographically diverse","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/european-medicines-agency-validates-gilead-133000551.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BSNM7G36.USD","LU0289739699.SGD","LU0109394709.USD","BK4215","IE00BZ1G4Q59.USD","LU0058720904.USD","BK4583","BK4585","LU1066053197.SGD","LU0889565916.HKD","IE00B19Z3B42.SGD","LU2089984988.USD","LU2468319806.SGD","IE00BKVL7J92.USD","BK4087","IE00B7SZLL34.SGD","IE0002270589.USD","CHMP","MAA","BK4532","GILD","LU1839511570.USD","BK4139","LU1430594728.SGD","LU1571399168.USD","IE00B3T34201.USD","BK4550","BK4566","IE00B19Z3581.USD","BK4568","BK4578","MDCO","LU1585245621.USD","BK4156","LU0234570918.USD","LU2087621335.USD","LU1066051498.USD","BK4588","LU0320765992.SGD"],"gpt_icon":0},{"id":"2513726695","title":"Fresenius Medical divesting select laboratory assets to Quest Diagnostics","url":"https://stock-news.laohu8.com/highlight/detail?id=2513726695","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513726695?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:06","pubTimestamp":1740402389,"startTime":"0","endTime":"0","summary":"Fresenius Medical (FMS) and Quest Diagnostics (DGX) announced that, under terms of a definitive acquisition agreement, Quest will acquire select as...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fresenius-medical-divesting-select-laboratory-assets-to-quest-diagnostics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fresenius-medical-divesting-select-laboratory-assets-to-quest-diagnostics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DGX","BK4583","BK4588","LU1854104046.USD","FMS","LU1854103824.USD","BK4196","BK4567","BK4585"],"gpt_icon":0},{"id":"2513726534","title":"BRIEF-FMC AG Divests Select Laboratory Assets To Quest Diagnostics","url":"https://stock-news.laohu8.com/highlight/detail?id=2513726534","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513726534?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:03","pubTimestamp":1740402181,"startTime":"0","endTime":"0","summary":"BRIEF-FMC AG Divests Select Laboratory Assets To Quest DiagnosticsFeb 24 (Reuters) - FMC AG FMEG.DE :FRESENIUS MEDICAL CARE ANNOUNCES DIVESTMENT OF SELECT LABORATORY ASSETS TO QUEST DIAGNOSTICSANNOUNC","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nTUA9DVLM7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU1854104046.USD","BK4196","BK4588","LU1854103824.USD","DGX","BK4583","BK4567"],"gpt_icon":0},{"id":"2513972507","title":"FMC Ag - Transition of Services Is Expected to Be Complete by Early 2026.","url":"https://stock-news.laohu8.com/highlight/detail?id=2513972507","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513972507?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:00","pubTimestamp":1740402004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nTUA9DVLM7:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1854103824.USD","BK4588","LU1854104046.USD","DGX","BK4585","BK4583","BK4196","BK4567"],"gpt_icon":0},{"id":"2513725001","title":"FMC Ag - Acquisition Is Expected to Close in Second Half of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2513725001","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513725001?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:00","pubTimestamp":1740402004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nTUA9DVLM7:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DGX","BK4583","BK4588","LU1854104046.USD","LU1854103824.USD","BK4196","BK4567","BK4585"],"gpt_icon":0},{"id":"2513250727","title":"FMC Ag - Financial Terms Were Not Disclosed","url":"https://stock-news.laohu8.com/highlight/detail?id=2513250727","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513250727?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:00","pubTimestamp":1740402004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nTUA9DVLM7:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1854103824.USD","BK4567","LU1854104046.USD","BK4588","BK4196","DGX","BK4583","BK4585"],"gpt_icon":0},{"id":"2513005725","title":"Fresenius Medical Care Announces Divestment of Select Laboratory Assets to Quest Diagnostics","url":"https://stock-news.laohu8.com/highlight/detail?id=2513005725","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513005725?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:00","pubTimestamp":1740402004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nTUA9DVLM7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1854104046.USD","BK4196","BK4588","BK4585","BK4583","LU1854103824.USD","DGX","BK4567"],"gpt_icon":0},{"id":"2513725094","title":"Press Release: Fresenius Medical Care Announces Divestment of Select Laboratory Assets to Quest Diagnostics","url":"https://stock-news.laohu8.com/highlight/detail?id=2513725094","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513725094?lang=en_us&edition=fundamental","pubTime":"2025-02-24 21:00","pubTimestamp":1740402000,"startTime":"0","endTime":"0","summary":"BAD HOMBURG, Germany and SECAUCUS, N.J., Feb. 24, 2025. -- Quest to provide comprehensive dialysis-related laboratory and water. testing services to Fresenius Medical Care owned and affiliated clinics. \"This transaction is part of our comprehensive portfolio optimization strategy to drive operational efficiencies and will provide enhanced experiences for patients and our clinical employees by integrating Quest Diagnostic's industry-leading expertise in laboratory medicine into our dialysis centers. This agreement is a step forward to allow us to remain focused on our core business of providing world-class dialysis care to every patient, every day,\" said Helen Giza, Chief Executive Officer of Fresenius Medical Care.  \"Much like Fresenius Medical Care, Quest Diagnostics is passionate about creating a healthier future for patients. These shared values, along with Quest's proven track record for quality care a","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4567","DGX","BK4196","FMS","BK4585","BK4588","LU1854103824.USD","LU1854104046.USD","SLCT","BK4583"],"gpt_icon":0},{"id":"2513549527","title":"Gilead Sciences, Inc. (GILD): Among Renaissance Technologies Portfolio’s Top Stock Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2513549527","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513549527?lang=en_us&edition=fundamental","pubTime":"2025-02-24 02:14","pubTimestamp":1740334499,"startTime":"0","endTime":"0","summary":"We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take a look at where Gilead Sciences, Inc.  stands against other Renaissance Technologies portfolio's top stock picks.The American quant hedge fundRenaissance Technologiesis known for using statistical and mathematical tools to drive its investment programs. It was founded in 1982 by Jim Simons, a mathematician who worked as a code breaker for the US National Security Agency during the Cold War. As of December 31, Renaissance Technologies had a portfolio valued at over $67.5 billion.READ ALSO:Cathie Wood’s Stock Portfolio: 2025 Stock PicksandJim Cramer’s February Portfolio: Top 10 Stocks.We scanned Renaissance Technologies’ 13F portfolio, as of December 31, 2024. From there, we picked the top 10 stocks according to their stake value and ranked them in ascending order.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-sciences-inc-gild-among-181459552.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MNQmain","BK4139","LU0234570918.USD",".IXIC","LU1066053197.SGD","LU2087621335.USD","BK4578","BK4532","PBC","BK4550","TSYW.SI","LU2468319806.SGD","TQQQ","IE00BSNM7G36.USD","GILD","LU0289739699.SGD","USJW.SI","IE00B7SZLL34.SGD","PSQ","BK4566","BK4588","IE00B3T34201.USD","LU1066051498.USD","IE00BKVL7J92.USD","NVIW.SI","USAW.SI","BK4568","NQmain","LU0109394709.USD","LU0320765992.SGD","SQQQ","LU0058720904.USD","LU2089984988.USD","QID","IE00BZ1G4Q59.USD","IE00B19Z3581.USD","LU1430594728.SGD","QLD","LU1571399168.USD","BK4585","IE0002270589.USD","LU1839511570.USD","BK4583","LU0889565916.HKD","LU1585245621.USD","IE00B19Z3B42.SGD"],"gpt_icon":1}],"pageSize":16,"totalPage":8,"pageCount":8,"totalSize":128}]}}